Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes

Proactive - Interviews for investors

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to discuss significant milestone with the FDA clearance of their oral appliance for treating obstructive sleep apnea (OSA) in children aged 6 to 17, particularly those requiring orthodontic treatment. This marks the first time an oral appliance has been approved for treating moderate to severe OSA in this pediatric group. Huntsman pointed out that around 20% of children in this age range suffer from OSA or related sleep disorders, which can lead to serious developmental and behavioral challenges like stunted growth, attention problems, and reduced IQ. The new device offers an alternative to traditional treatments such as surgery, which often fail to provide lasting results. In addition to this milestone, Vivos Therapeutics has also achieved another regulatory victory, securing new CPT medical codes from the American Medical Association (AMA) for all Vivos CARE oral medical devices. These codes, set to take effect on January 1, 2025, will make OSA treatments more accessible and affordable by improving the exchange of standardized information in healthcare. This approval comes after Vivos had earlier gained Medicare coverage for their devices, further expanding the availability of their treatment to children. With the new CPT codes, Vivos aims to enhance patient care, outcomes, and reduce costs, positioning the company to significantly expand its mission of making OSA treatments more widely available across the U.S. #proactiveinvestors #vivostherapeuticsinc #nasdaq #vvos #sleepapnea#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #PediatricOSA #SleepApneaTreatment #KirkHuntsman #FDAApproval #HealthcareInnovation #ChildrensHealth #ObstructiveSleepApnea #MedicalBreakthrough #OrthodonticCare #ProactiveInvestors #HealthTech